OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Coleman on the Use of Immunotherapy in Cervical Cancer

October 10th 2019

Robert L. Coleman, MD, FACOG, FACS, professor in the Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the use of immunotherapy in patients with cervical cancer.

Next Steps for Immunoscore in Oncology

October 10th 2019

Jerome Galon, PhD, research director, French Institute of Health and Medical Research, discusses next steps with Immunoscore in oncology.

Dr. DiPersio on Investigational Targeted Cellular Therapies in AML

October 10th 2019

John F. DiPersio, MD, PhD, discusses the current state of CAR T-cell therapy, dual affinity re-targeting, bi-specific T-cell engagers, and antibody-drug conjugates for acute myeloid leukemia treatment.

Dr. Ledermann on Rationale for ARIEL3 Trial in Ovarian Cancer

October 9th 2019

Jonathan A. Ledermann, MD, discusses the rationale for the randomized, double-blind, placebo-controlled, phase III ARIEL3 trial which explored rucaparib as maintenance therapy in women with high-grade, recurrent ovarian cancer who previously received platinum-based chemotherapy.

Dr. Sonpavde on Enfortumab Vedotin Data in Urothelial Cancer

October 9th 2019

Guru P. Sonpavde, MD, director, Bladder Cancer, and physician, Dana-Farber Cancer Institute, discusses the results of the phase II EV-201 trial in patients with locally advanced or metastatic urothelial cancer.

Dr. Wang on Toxicity Profiles of Ibrutinib, Acalabrutinib, and Zanubrutinib in MCL

October 9th 2019

Michael Wang, MD, discusses the toxicity profiles of the BTK inhibitors ibrutinib, acalabrutinib, and zanubrutinib in mantle cell lymphoma.

Dr. Westbrook on Combatting Tumor Heterogeneity in HER2+ Breast Cancer

October 9th 2019

Kelly E. Westbrook, MD, discusses combatting tumor heterogeneity in patients with HER2-positive breast cancer.

Dr. Holman on Screening for Ovarian Cancer

October 9th 2019

Laura L. Holman, MD, discusses screening options for ovarian cancer.

Dr. Randall on Using Pexidartinib to Treat Tenosynovial Giant Cell Tumor

October 9th 2019

R. Lor Randall, MD, FACS, discusses using pexidartinib to treat tenosynovial giant cell tumor.

Dr. Oaknin on the Rationale for the GARNET Trial in Endometrial Cancer

October 9th 2019

Ana Oaknin, MD, principal investigator, Gynecological Malignancies Group, Vall d’Hebron Institute of Oncology, head of Gynecologic Tumors Unit, senior medical oncologist and attending physician, Medical Oncology Department, Vall d’Hebron University Hospital, discusses the rationale for the phase I/II GARNET trial in endometrial cancer.

Dr. Cristofanilli on Data With Lasofoxifene in ESR1-Mutant Breast Cancer

October 9th 2019

Massimo Cristofanilli, MD, professor of medicine, Hematology Oncology Division, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, discusses data with lasofoxifene in women with ESR1-mutant breast cancer.

Dr. Untch on the Expanding Use of Biosimilars

October 9th 2019

Michael Untch, MD, PhD, discusses the widespread use of biosimilars in Europe.

Dr. Dahut on Using MRI Screening for Prostate Cancer

October 9th 2019

William L. Dahut, MD, discusses multiparametric magnetic resonance imaging as an alternative screening technique to prostate-specific antigen testing in prostate cancer.

Dr. Sasine on Predicting Individual Benefit with CAR T Cells

October 9th 2019

Joshua P. Sasine, MD, PhD, discusses the challenges in predicting a patient’s individual benefit with CAR T-cell therapy in hematologic malignancies.

Dr. Pili on the Challenges of Translocation RCC

October 8th 2019

Roberto Pili, MD, discusses clinical challenges in translocation renal cell carcinoma.

Dr. Weber on Rationale for the CheckMate-238 Trial in Melanoma

October 8th 2019

Jeffrey S. Weber, MD, PhD, discusses the rationale behind the randomized, double-blind, phase III CheckMate-238 trial in resected stage III or IV melanoma.

Dr. Gomella on the Challenges of Genetic Testing in Prostate Cancer

October 8th 2019

Leonard G. Gomella, MD, discusses the challenges of genetic testing in prostate cancer.

Dr. Anders Discusses the Use of Neratinib/Capecitabine for HER2-Positive Brain Metastases

October 8th 2019

Carey Anders, MD, director, Brain and Spine Metastasis Program, Duke Cancer Institute, discusses the use of neratinib (Nerlynx) and capecitabine in patients with HER2-positive breast cancer that has metastasized to the brain.

Impact of BTK Inhibition on Monocytic Myeloid-Derived Suppressor Cells in CLL

October 8th 2019

Arantxa Romero-Toledo, PhD student, at the Centre for Haemato-Oncology, Barts Cancer Institute, discusses the impact of BTK inhibition on monocytic myeloid-derived suppressor cells (MDSCs) in chronic lymphocytic leukemia (CLL).

Dr. O'Reilly on Agents in Development in Advanced Pancreatic Cancer

October 8th 2019

Eileen O'Reilly, MD, associate director for clinical research and medical oncologist at Memorial Sloan Kettering Cancer Center, discusses agents in development in advanced pancreatic cancer.